INT21185

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 1982
Last Reported 2010
Negated 1
Speculated 6
Reported most in Abstract
Documents 213
Total Number 219
Disease Relevance 13.49
Pain Relevance 157.75

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Ptprg)
Anatomy Link Frequency
brain 36
hippocampus 9
hypothalamus 6
striatum 6
amygdala 6
Ptprg (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 149 100.00 Very High Very High Very High
Immobilon 21 100.00 Very High Very High Very High
agonist 781 99.98 Very High Very High Very High
Buprenorphine 129 99.92 Very High Very High Very High
narcan 147 99.84 Very High Very High Very High
Hippocampus 80 99.84 Very High Very High Very High
opioid receptor 212 99.70 Very High Very High Very High
Opioid 355 99.68 Very High Very High Very High
Substantia nigra 91 99.68 Very High Very High Very High
Potency 27 99.68 Very High Very High Very High
Disease Link Frequency Relevance Heat
Bordatella Infection 38 99.84 Very High Very High Very High
Urological Neuroanatomy 24 99.32 Very High Very High Very High
Tics 9 97.30 Very High Very High Very High
Diabetes Mellitus 30 97.24 Very High Very High Very High
Glioma 26 97.16 Very High Very High Very High
Opiate Addiction 22 96.16 Very High Very High Very High
Neuroblastoma 15 95.80 Very High Very High Very High
Sprains And Strains 20 90.80 High High
Neuropathic Pain 11 90.76 High High
INFLAMMATION 12 88.56 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Sensitivity for autoradiographic visualization of [35S]GTPgammaS binding was improved two- to threefold in rat brain sections by optimizing assay conditions.
GTPgammaS Binding (binding) of in brain
1) Confidence 0.47 Published 2001 Journal Eur. J. Pharmacol. Section Abstract Doc Link 11430907 Disease Relevance 0 Pain Relevance 0.28
Basal and NSB were low in glycylglycine buffer compared to Tris or HEPES buffers, and agonist-stimulated [35S]GTPgammaS binding was more easily observed.
GTPgammaS Binding (binding) of associated with agonist
2) Confidence 0.47 Published 2001 Journal Eur. J. Pharmacol. Section Abstract Doc Link 11430907 Disease Relevance 0 Pain Relevance 0.38
In brain sections, chronic heroin administration decreased DAMGO-stimulated [35S]GTPgammaS binding in medial thalamus and amygdala, with no effect in cingulate cortex or nucleus accumbens.
GTPgammaS Binding (binding) of in medial associated with nucleus accumbens, thalamus and amygdala
3) Confidence 0.42 Published 2005 Journal Life Sci. Section Abstract Doc Link 15890372 Disease Relevance 0 Pain Relevance 0.56
To extend these findings, the present study investigated DAMGO-stimulated [35S]GTPgammaS binding in membrane homogenates and coronal sections from rats non-contingently administered heroin.
GTPgammaS Binding (binding) of
4) Confidence 0.42 Published 2005 Journal Life Sci. Section Abstract Doc Link 15890372 Disease Relevance 0 Pain Relevance 0.41
Previous studies have shown that chronic opiate treatment decreases mu opioid-stimulated [35S]GTPgammaS binding in specific brain regions.
GTPgammaS Binding (binding) of in brain associated with opiate and opioid
5) Confidence 0.42 Published 2005 Journal Life Sci. Section Abstract Doc Link 15890372 Disease Relevance 0 Pain Relevance 0.33
GTPgammaS saturation analysis showed that chronic heroin treatment decreased the Bmax, and increased the K(D), of DAMGO-stimulated [35S]GTPgammaS binding.
GTPgammaS Binding (binding) of
6) Confidence 0.42 Published 2005 Journal Life Sci. Section Abstract Doc Link 15890372 Disease Relevance 0 Pain Relevance 0.62
Cys(Npys) blocked [35S]GTP gamma S binding as well as IAP-catalyzed ADP-ribosylation in purified Go.
GTP gamma S Binding (binding) of
7) Confidence 0.41 Published 1990 Journal Mol. Pharmacol. Section Abstract Doc Link 2166901 Disease Relevance 0.06 Pain Relevance 0.35
Chronic heroin administration also reduced [35S]GTPgammaS binding stimulated by the principal metabolite of heroin, 6-monoacetylmorphine.
GTPgammaS Binding (binding) of
8) Confidence 0.36 Published 2005 Journal Life Sci. Section Abstract Doc Link 15890372 Disease Relevance 0 Pain Relevance 0.61
We evaluated, using quantitative autoradiography, the effect of these antidepressant treatments on [35S]GTPgammaS binding stimulated by the 5-HT1A receptor agonist 8-OH-DPAT, a measure of the capacity of 5-HT1A receptors to activate G proteins.
GTPgammaS Binding (binding) of associated with antidepressant and agonist
9) Confidence 0.35 Published 2006 Journal Int. J. Neuropsychopharmacol. Section Abstract Doc Link 16035959 Disease Relevance 0 Pain Relevance 0.48
Chronic administration of amitriptyline resulted in a marked increase in 5-HT1A receptor-stimulated [35S]GTPgammaS binding in the hippocampus which was accompanied by an increase in 5-HT1A receptor number. 5-HT1A receptor-stimulated [35S]GTPgammaS binding in the hippocampus was also increased by chronic treatment with the highest dose of venlafaxine; 5-HT1A receptor number, however, was not significantly altered.
GTPgammaS Binding (binding) of in hippocampus associated with hippocampus and endep
10) Confidence 0.35 Published 2006 Journal Int. J. Neuropsychopharmacol. Section Abstract Doc Link 16035959 Disease Relevance 0 Pain Relevance 0.54
In serotonergic cell body areas (i.e. dorsal and median raphe nuclei), 5-HT1A receptor-stimulated [35S]GTPgammaS binding was not altered by chronic administration of amitriptyline, sertraline or venlafaxine.
GTPgammaS Binding (binding) of in dorsal associated with endep and raphe
11) Confidence 0.35 Published 2006 Journal Int. J. Neuropsychopharmacol. Section Abstract Doc Link 16035959 Disease Relevance 0 Pain Relevance 0.65
Improved sensitivity was due to decreased NSB and basal [35S]GTPgammaS binding and agonist-stimulated binding were similarly affected for each receptor system.
GTPgammaS Binding (binding) of associated with agonist
12) Confidence 0.35 Published 2001 Journal Eur. J. Pharmacol. Section Abstract Doc Link 11430907 Disease Relevance 0 Pain Relevance 0.37
Non-specific (NSB), basal and agonist-stimulated [35S]GTPgammaS binding were measured, using methadone, 5-carboxamidotryptamine and epinephrine for mu-opiate receptors, 5-HT(1A) receptors and alpha(2)-adrenoceptors.
GTPgammaS Binding (binding) of associated with agonist, opiate and methadone
13) Confidence 0.35 Published 2001 Journal Eur. J. Pharmacol. Section Abstract Doc Link 11430907 Disease Relevance 0 Pain Relevance 0.32
The assay conditions described should extend the use of agonist-stimulated [35S]GTPgammaS autoradiography to receptors, which produce low levels of [35S]GTPgammaS binding and to the measurement of changes in receptor-G protein coupling.
GTPgammaS Binding (binding) of associated with agonist
14) Confidence 0.35 Published 2001 Journal Eur. J. Pharmacol. Section Abstract Doc Link 11430907 Disease Relevance 0 Pain Relevance 0.34
Control rats were injected with either saline or a single acute injection of morphine (20 mg/kg). mu opioid-stimulated [35S]GTPgammaS binding was measured by autoradiography of brain sections in the presence and absence of the mu opioid-selective agonist DAMGO.
GTPgammaS Binding (binding) of in brain associated with agonist, opioid and morphine
15) Confidence 0.35 Published 1996 Journal J. Neurosci. Section Abstract Doc Link 8786444 Disease Relevance 0 Pain Relevance 1.25
In contrast to its inhibitory effects on DAMGO-induced GTP gamma S binding, buprenorphine stimulated N/OFQ-induced GTP gamma S binding in male P2 nucleus accumbens and lateral septum.
GTP gamma S Binding (binding) of in nucleus accumbens associated with nucleus accumbens and buprenorphine
16) Confidence 0.35 Published 2004 Journal Brain Res. Dev. Brain Res. Section Abstract Doc Link 15246701 Disease Relevance 0.11 Pain Relevance 1.79
Naloxone used in combination with buprenorphine blocked the inhibition by buprenorphine alone on DAMGO-induced GTP gamma S binding.
GTP gamma S Binding (binding) of associated with narcan and buprenorphine
17) Confidence 0.35 Published 2004 Journal Brain Res. Dev. Brain Res. Section Abstract Doc Link 15246701 Disease Relevance 0.12 Pain Relevance 1.76
Methadone diminished DAMGO-induced GTP gamma S binding in almost all monitored brain regions of the dam but had few effects on their N/OFQ-induced GTP gamma S binding.
GTP gamma S Binding (binding) of in brain associated with methadone
18) Confidence 0.35 Published 2004 Journal Brain Res. Dev. Brain Res. Section Abstract Doc Link 15246701 Disease Relevance 0.13 Pain Relevance 1.72
Buprenorphine and/or methadone gestational treatment attenuated DAMGO-induced GTP gamma S binding in some dam and male P2 mesolimbic regions.
GTP gamma S Binding (binding) of associated with methadone and buprenorphine
19) Confidence 0.35 Published 2004 Journal Brain Res. Dev. Brain Res. Section Abstract Doc Link 15246701 Disease Relevance 0.15 Pain Relevance 1.59
Methadone diminished DAMGO-induced GTP gamma S binding in almost all monitored brain regions of the dam but had few effects on their N/OFQ-induced GTP gamma S binding.
GTP gamma S Binding (binding) of in brain associated with methadone
20) Confidence 0.35 Published 2004 Journal Brain Res. Dev. Brain Res. Section Abstract Doc Link 15246701 Disease Relevance 0.14 Pain Relevance 1.69

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox